Clinical Trial Update: Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial of emricasan, an oral caspase inhibitor, in subjects with NASH cirrhosis and severe portal hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Non-alcoholic Steatohepatitis
• Portal Hypertension

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Histogen | Conditions: Cirrhosis, Portal Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2022-01-14